Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PLURIMES

Financiado

Cerrado

Pluripotent stem cell resources for mesodermal medicine

Harnessing the capacity of pluripotent stem cells (PSCs) to produce functional cell types with precision and at scale will enable new treatment modalities for degenerative diseases. A major target for such therapies is mesodermal... ver más

31/01/2018

THE CHANCELLOR MAS...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-01-31 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

THE CHANCELLOR MASTERS AND S...

0.00€ | Lider

TUD

N.D. | Participante

CERBM-GIE

N.D. | Participante

STEMCELL TECHNOLOGIES UK LTD

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FORMAT FORMAT a novel medium FOr Revolutionizing stem cell MAnufac... 150K€ Cerrado

SAF2012-40149-C02-01 ESTUDIO PRECLINICO PARA EVALUAR CELULAS MESENQUIMALES HUMANA... 70K€ Cerrado

REPROWORM Safeguarding Cell Identities Mechanisms Counteracting Cel... 1M€ Cerrado

PROMETHEUS Novel Cells for Organ Repair 3M€ Cerrado

TRANSHESC Generation of stable transgenic embryonic stem cell lines 243K€ Cerrado

SAF2016-75456-R PAPEL DE DIDO EN LA AUTORREPLICACION Y DIFERENCIACION DE LAS... 424K€ Cerrado

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Harnessing the capacity of pluripotent stem cells (PSCs) to produce functional cell types with precision and at scale will enable new treatment modalities for degenerative diseases. A major target for such therapies is mesodermal tissue, muscle, bone and cartilage. The goal of PluriMes is to create a bioengineering platform for directing PSCs into specific classes of mesodermal/mesenchymal progenitor. The project pulls together stem cell experts, genetic engineers, developmental biologists, cell therapy pioneers, bioengineers and specialist SMEs in a cross-disciplinary collaborative effort. Close-working between partners will be maximised through specialist workshops, laboratory exchange schemes, regular workpackage meetings, and joint Deliverables. The concept underlying PluriMes is that refined control of early fate decisions to produce correctly specified progenitors will be obtained through confronting developmental principles with engineering logic. We aim to define ground states and resolve issues of hierarchy, heterogeneity and stability in order to provide standardised PSC and mesodermal progenitor cell populations. A toolbox of fluorescent reporters will be developed for live cell tracking. Cutting edge bioengineering approaches will be implemented for dynamic topological administration of morphogens, matrices, small molecule modulators and siRNAs in 2D and 3D contexts. Through SME involvement, culture systems will be optimised for specification and subsequent stable expansion of mesodermal progenitors. The capacity of PSC-derived mesodermal cells for maturation into skeletal muscle, bone and cartilage will be tested in vitro and in vivo using lineage reporters. Potency will then be evaluated in pre-clinical disease models. Scale up protocols will be implemented in partnership with SMEs using the latest bioreactor technologies. Finally, GMP compliance and validated applicability to clinical grade stem cells will underpin future cell therapy propositions.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores